Glycoprotein IIb-IIIa inhibitor: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett |
imported>Gareth Leng No edit summary |
||
| Line 1: | Line 1: | ||
{{subpages}} | |||
'''Glycoprotein IIb/IIIa inhibitors''' include [[eptifibatide]] and [[tirofiban]]. These medication block the [[platelet glycoprotein GPIIb-IIIa complex]] and are used for treating [[acute coronary syndrome]]s.<ref name="pmid19458369">{{cite journal| author=Hillis LD, Lange RA| title=Optimal management of acute coronary syndromes. | journal=N Engl J Med | year= 2009 | volume= 360 | issue= 21 | pages= 2237-40 | pmid=19458369 | '''Glycoprotein IIb/IIIa inhibitors''' include [[eptifibatide]] and [[tirofiban]]. These medication block the [[platelet glycoprotein GPIIb-IIIa complex]] and are used for treating [[acute coronary syndrome]]s.<ref name="pmid19458369">{{cite journal| author=Hillis LD, Lange RA| title=Optimal management of acute coronary syndromes. | journal=N Engl J Med | year= 2009 | volume= 360 | issue= 21 | pages= 2237-40 | pmid=19458369 | ||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19458369 | doi=10.1056/NEJMe0902632 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref> | | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19458369 | doi=10.1056/NEJMe0902632 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref> | ||
Latest revision as of 10:09, 17 October 2010
Glycoprotein IIb/IIIa inhibitors include eptifibatide and tirofiban. These medication block the platelet glycoprotein GPIIb-IIIa complex and are used for treating acute coronary syndromes.[1]
References
- ↑ Hillis LD, Lange RA (2009). "Optimal management of acute coronary syndromes.". N Engl J Med 360 (21): 2237-40. DOI:10.1056/NEJMe0902632. PMID 19458369. Research Blogging.